Versuchen GOLD - Frei
Hyundai preps COO Garg to take over as India boss
Mint Mumbai
|September 16, 2025
Hyundai Motor Co. is set to elevate its India chief operations officer (COO) Tarun Garg as managing director and chief executive of its domestic unit, an executive directly aware of the plan said.
Garg would be the first Indian to lead Hyundai Motor India, at a time the Korean giant is fighting to keep its No.2 position in the Indian car market.
Garg is expected to take the helm around the inauguration of Hyundai’s new Talegaon plant in Maharashtra, the executive said on the condition of anonymity. The facility is slated to begin producing 250,000 units within the next three years, with its opening likely in the final quarter of 2025.
“The strategy is part of Hyundai’s ongoing plan to promote non-Koreans into leadership positions in foreign markets where it has a significant presence,” the executive said. This push began with the appointment of Jose Munoz as the first non-Korean President of Hyundai in January, following his tenure as global COO since April 2019.
With the company eyeing an India hand to lead its operations, the global management led by Munoz narrowed down on Garg, who joined Hyundai in December 2019 as director of sales. He was promoted as COO in January 2023, where he was working closely with Munoz.
Hyundai Motor India declined to comment. “What may or may not happen in the future is purely speculative and as a listed company, we do not comment on speculation.
Diese Geschichte stammt aus der September 16, 2025-Ausgabe von Mint Mumbai.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size
